{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T22:27:08Z","timestamp":1773872828078,"version":"3.50.1"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2026,3,1]]},"abstract":"\n Importance<\/jats:title>\n Acne commonly affects transgender individuals prescribed gender-affirming hormone therapy, yet population-level incidence data remain limited.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the incidence of acne and moderate to severe acne in transgender individuals, including those initiating gender-affirming hormone therapy, with matched cisgender individuals.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n A retrospective matched cohort study of electronic health record data was carried out across 4 Kaiser Permanente health plan regions. Index dates were the earliest documentation of transgender status, ranging from January 2006 to February 2022, with up to 5 years of follow-up. Participants included individuals without baseline acne, transmasculine individuals, and transfeminine individuals matched with cisgender male and female individuals. Analyses were conducted from November 2024 to November 2025.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome was incident acne (first acne-coded visit after the index date). The secondary outcome was moderate to severe acne (incident acne followed by prescription fill for isotretinoin or 30 or more days of oral antibiotics). Exploratory analyses compared acne care utilization by transgender status.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Overall, 280\u202f997 individuals without baseline acne, including 11\u202f234 transmasculine and 9486 transfeminine individuals, were matched to 132\u202f462 cisgender men and 127\u202f815 cisgender women on age, self-reported race and ethnicity (25\u202f340 Asian [9.0%]; 23\u202f234 non-Hispanic Black [8.3%]; 56\u202f876 Hispanic [20.2%]; 153\u202f666 non-Hispanic White [54.7%]; 6989 other [2.5%]), enrollment year, and region. Of these, 12\u202f156 transgender individuals initiated gender-affirming hormone therapy after the index date. The mean (SD) age at index date was 27.7 (10.0) years for transmasculine individuals and 33.2 (13.5) years for transfeminine individuals. Cumulative incidence of acne at 5 years was 15.8% in transmasculine individuals, 3.8% in matched cisgender male individuals, and 10.5% in matched cisgender female individuals and was 6.0% in transfeminine individuals, 2.9% in matched cisgender men, and 8.4% in matched cisgender women. Acne risk in transmasculine individuals was highest in the first year after testosterone initiation (vs matched cisgender male individuals: hazard ratio (HR), 8.29; 95% CI, 7.11-9.68; vs matched cisgender female individuals: HR, 2.63; 95% CI, 2.33-2.97) and remained higher in subsequent years than among cisgender men (HR, 5.29; 95% CI, 4.45-6.28) and cisgender women (HR, 1.69; 95% CI, 1.46-1.96). Acne risk was higher in transfeminine individuals after starting estradiol than cisgender men (HR, 1.56; 95% CI, 1.31-1.84) and lower than cisgender women (HR, 0.53; 95% CI, 0.46-0.62). Moderate to severe acne incidence followed similar patterns.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n This study revealed distinct acne incidence patterns in transgender individuals compared with matched cis male and female cohorts. Clinicians should monitor and treat acne in transmasculine individuals prescribed testosterone per clinical guidelines, particularly during the first year. Clinicians should also recognize that acne may develop in transfeminine individuals after estradiol initiation.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.5597","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T16:00:27Z","timestamp":1769011227000},"page":"255","source":"Crossref","is-referenced-by-count":0,"title":["Acne Incidence and Severity in Transgender Individuals"],"prefix":"10.1001","volume":"162","author":[{"given":"Courtney A.","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oumaima","family":"Kaabi","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amita K.","family":"Manatunga","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy L.","family":"Lash","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Silverberg","sequence":"additional","affiliation":[{"name":"Division of Research, Kaiser Permanente Northern California, Pleasanton"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darios","family":"Getahun","sequence":"additional","affiliation":[{"name":"Department of Research & Evaluation, Kaiser Permanente Southern California, Pasadena"},{"name":"Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, California"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suma","family":"Vupputuri","sequence":"additional","affiliation":[{"name":"Mid-Atlantic Permanente Research Institute, Kaiser Permanente Mid-Atlantic States, Washington, DC"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney E.","family":"McCracken","sequence":"additional","affiliation":[{"name":"Center for Research and Evaluation, Kaiser Permanente Georgia, Atlanta"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suephy C.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Duke University School of Medicine, Durham, North Carolina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vin","family":"Tangpricha","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Metabolism, and Lipids, Department of Medicine, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Goodman","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Howa","family":"Yeung","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Emory University School of Medicine, Atlanta, Georgia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"2","key":"doi250068r1","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jaad.2019.03.023","article-title":"Issues in transgender dermatology: a systematic review of the literature.","volume":"81","author":"Sullivan","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi250068r2","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1016\/j.jaad.2022.03.013","article-title":"Acne risk in transgender and gender diverse populations: a retrospective, comparative cohort study.","volume":"87","author":"Gao","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi250068r3","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1016\/j.jaad.2020.02.053","article-title":"Prevalence of moderate to severe acne in transgender adults: a cross-sectional survey.","volume":"83","author":"Yeung","year":"2020","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250068r4","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jamadermatol.2020.5353","article-title":"Moderate-to-severe acne and mental health symptoms in transmasculine persons who have received testosterone.","volume":"157","author":"Braun","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"2","key":"doi250068r5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jaad.2018.12.040","article-title":"Risk factors for acne development in the first 2 years after initiating masculinizing testosterone therapy among transgender men.","volume":"81","author":"Park","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi250068r6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1001\/jamadermatol.2020.5347","article-title":"Incidence and factors associated with acne among transgender patients receiving masculinizing hormone therapy.","volume":"157","author":"Thoreson","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"12","key":"doi250068r7","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-018121","article-title":"Cohort profile: Study of Transition, Outcomes and Gender (STRONG) to assess health status of transgender people.","volume":"7","author":"Quinn","year":"2017","journal-title":"BMJ Open"},{"key":"doi250068r8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1080\/26895269.2022.2100644","article-title":"Standards of care for the health of transgender and gender diverse people, version 8.","volume":"23","author":"Coleman","year":"2022","journal-title":"Int J Transgend Health"},{"issue":"11","key":"doi250068r9","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1210\/jc.2017-01658","article-title":"Endocrine treatment of gender-dysphoric\/gender-incongruent persons: an Endocrine Society clinical practice guideline.","volume":"102","author":"Hembree","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"doi250068r10","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1684\/ejd.2015.2606","article-title":"Validating the diagnostic code for acne in a tertiary care dermatology centre.","volume":"25","author":"Ejaz","year":"2015","journal-title":"Eur J Dermatol"},{"issue":"5","key":"doi250068r11","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jaad.2020.07.075","article-title":"Validating the optimal classification approach using ICD-10 codes to identify dermatology patients with acne.","volume":"84","author":"Barbieri","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"doi250068r12","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.jaad.2015.01.048","article-title":"Duration of oral antibiotic therapy for the treatment of adult acne: a retrospective analysis investigating adherence to guideline recommendations and opportunities for cost-savings.","volume":"72","author":"Straight","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"9596","key":"doi250068r13","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"doi250068r14","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1684\/ejd.2024.4758","article-title":"The effects of gender-affirming testosterone therapy in transgender men on the development of acne, acne severity and the relationship with clinical parameters: a three-year follow-up study.","volume":"34","author":"Madsen","year":"2024","journal-title":"Eur J Dermatol"},{"issue":"1","key":"doi250068r15","doi-asserted-by":"publisher","first-page":"5754","DOI":"10.1038\/s41598-020-62715-3","article-title":"Systematic review of the epidemiology of acne vulgaris.","volume":"10","author":"Heng","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"doi250068r16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/bjd\/ljae352","article-title":"Global, regional and national burdens of acne vulgaris in adolescents and young adults aged 10-24?years from 1990 to 2021: a trend analysis.","volume":"192","author":"Zhu","year":"2025","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi250068r17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.eprac.2023.02.002","article-title":"Incidence and factors associated with acne in transgender adolescents on testosterone: a retrospective cohort study.","volume":"29","author":"Chu","year":"2023","journal-title":"Endocr Pract"},{"issue":"8","key":"doi250068r18","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1210\/jcem.85.8.6710","article-title":"Effects of sex steroid deprivation\/administration on hair growth and skin sebum production in transsexual males and females.","volume":"85","author":"Giltay","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"doi250068r19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s42000-024-00532-3","article-title":"Priorities for efficacy trials of gender-affirming hormone therapy with estrogen: collaborative design and results of a community survey.","volume":"23","author":"Grock","year":"2024","journal-title":"Hormones (Athens)"},{"issue":"2","key":"doi250068r20","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1001\/jamadermatol.2023.5355","article-title":"Lived experience of acne and acne treatment in transgender patients.","volume":"160","author":"Gold","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi250068r21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1001\/jamadermatol.2019.4818","article-title":"Association of race\/ethnicity and sex with differences in health care use and treatment for acne.","volume":"156","author":"Barbieri","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"7","key":"doi250068r22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1001\/jamadermatol.2024.1420","article-title":"Isotretinoin for acne in transgender and gender-diverse individuals receiving masculinizing hormone therapy.","volume":"160","author":"Choe","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi250068r23","doi-asserted-by":"publisher","first-page":"1006.e1","DOI":"10.1016\/j.jaad.2023.12.017","article-title":"Guidelines of care for the management of acne vulgaris.","volume":"90","author":"Reynolds","year":"2024","journal-title":"J Am Acad Dermatol"},{"key":"doi250068r25","volume-title":"Examining Health Outcomes for People Who Are Transgender","author":"Goodman","year":"2019"},{"key":"doi250068r24","unstructured":"LGBTQI+ People Are Underinsured and Experience Health Insurance Discrimination in Key Areas. Center for American Progress. June 30, 2025. Accessed July 14, 2025. https:\/\/www.americanprogress.org\/article\/lgbtqi-people-are-underinsured-and-experience-health-insurance-discrimination-in-key-areas\/"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2844107\/jamadermatology_smith_2026_oi_250068_1772642724.54078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T15:00:25Z","timestamp":1773846025000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2844107"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.5597","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3,1]]}}}